Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
received:
29
04
2024
accepted:
07
08
2024
medline:
15
8
2024
pubmed:
15
8
2024
entrez:
14
8
2024
Statut:
epublish
Résumé
Despite major advances in molecular profiling and classification of primary brain tumors, personalized treatment remains limited for most patients. Here, we explored the feasibility of individual molecular profiling and the efficacy of biomarker-guided therapy for adult patients with primary brain cancers in the real-world setting within the molecular tumor board Freiburg, Germany. We analyzed genetic profiles, personalized treatment recommendations, and clinical outcomes of 102 patients with 21 brain tumor types. Alterations in the cell cycle, BRAF, and mTOR pathways most frequently led to personalized treatment recommendations. Molecularly informed therapies were recommended in 71% and implemented in 32% of patients with completed molecular diagnostics. The disease control rate following targeted treatment was 50% and the overall response rate was 30%, with a progression-free survival 2/1 ratio of at least 1.3 in 31% of patients. This study highlights the efficacy of molecularly guided treatment and the need for biomarker-stratified trials in brain cancers.
Identifiants
pubmed: 39143272
doi: 10.1038/s41698-024-00674-y
pii: 10.1038/s41698-024-00674-y
doi:
Types de publication
Journal Article
Langues
eng
Pagination
180Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : SCHE 1807/3-1
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 441891347
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : CRC1479
Organisme : Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)
ID : 2018_A38
Organisme : Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
ID : 01EO2103
Informations de copyright
© 2024. The Author(s).
Références
Bedard, P. L., Hyman, D. M., Davids, M. S. & Siu, L. L. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395, 1078–1088 (2020).
pubmed: 32222192
doi: 10.1016/S0140-6736(20)30164-1
Ettinger, D. S. et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 20, 497–530 (2022).
doi: 10.6004/jnccn.2022.0025
Harbeck, N. & Gnant, M. Breast cancer. Lancet 389, 1134–1150 (2017).
pubmed: 27865536
doi: 10.1016/S0140-6736(16)31891-8
Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324–1334 (2015).
pubmed: 26342236
doi: 10.1016/S1470-2045(15)00188-6
Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial. Cancer Discov. 7, 586–595 (2017).
pubmed: 28365644
doi: 10.1158/2159-8290.CD-16-1396
Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 42, 47–58 (2024).
doi: 10.1200/JCO.23.02005
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol. 23, 1231–1251 (2021).
pubmed: 34185076
pmcid: 8328013
doi: 10.1093/neuonc/noab106
Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170–186 (2021).
pubmed: 33293629
doi: 10.1038/s41571-020-00447-z
Goldbrunner, R. et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncol. 23, 1821–1834 (2021).
pubmed: 34181733
pmcid: 8563316
doi: 10.1093/neuonc/noab150
Rudà, R. et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro-Oncol. 20, 445–456 (2018).
pubmed: 29194500
doi: 10.1093/neuonc/nox166
Rudà, R. et al. EANO-EURACAN-SNO guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro-Oncol. 24, 2015–2034 (2022).
pubmed: 35908833
pmcid: 9713532
doi: 10.1093/neuonc/noac188
Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589–601 (2023).
pubmed: 37272516
doi: 10.1056/NEJMoa2304194
Brown, M. C., Ashley, D. M. & Khasraw, M. Low tumor mutational burden and immunotherapy in gliomas. Trends Cancer 8, 345–346 (2022).
pubmed: 35093301
doi: 10.1016/j.trecan.2022.01.006
Raizer, J. J. et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncol. 12, 95–103 (2010).
pubmed: 20150372
doi: 10.1093/neuonc/nop015
Hoefflin, R. et al. Personalized clinical decision making through implementation of a molecular tumor board: a German single-center experience. JCO Precis. Oncol. 2, PO.18.00105 (2018).
pubmed: 32913998
pmcid: 7446498
Illert, A. L. et al. The German Network for Personalized Medicine to enhance patient care and translational research. Nat. Med. 29, 1298–1301 (2023).
pubmed: 37280276
doi: 10.1038/s41591-023-02354-z
Horak, P. et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov. 11, 2780–2795 (2021).
pubmed: 34112699
doi: 10.1158/2159-8290.CD-21-0126
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
doi: 10.1038/nature07385
Cancer Genome Atlas Research Network et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
doi: 10.1056/NEJMoa1402121
Merchant, M. et al. Tumor mutational burden and immunotherapy in gliomas. Trends Cancer 7, 1054–1058 (2021).
pubmed: 34580037
pmcid: 10423405
doi: 10.1016/j.trecan.2021.08.005
Mock, A. et al. NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. NPJ Precis. Oncol. 7, 109 (2023).
pubmed: 37884744
pmcid: 10603123
doi: 10.1038/s41698-023-00458-w
Horak, P. et al. Precision oncology based on omics data: The NCT Heidelberg experience. Int. J. Cancer 141, 877–886 (2017).
pubmed: 28597939
doi: 10.1002/ijc.30828
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017).
pubmed: 28890946
Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980–D985 (2014).
pubmed: 24234437
doi: 10.1093/nar/gkt1113
Renovanz, M. et al. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncol. Adv. 5, vdad012 (2023).
Buyse, M. et al. Progression-free survival ratio as end point for phase II trials in advanced solid tumors. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 29, e451–e452 (2011).
doi: 10.1200/JCO.2010.34.0380
Padovan, M. et al. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis. Eur. J. Cancer 191, 112959 (2023).
pubmed: 37481865
doi: 10.1016/j.ejca.2023.112959
Lazaridis, L. et al. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma. J. Cancer Res. Clin. Oncol. 149, 3513–3526 (2023).
pubmed: 35953681
doi: 10.1007/s00432-022-04050-w
Luger, A.-L. et al. Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis. J. Neurooncol. 159, 243–259 (2022).
pubmed: 35864412
pmcid: 9424147
doi: 10.1007/s11060-022-04049-w
Hönikl, L. S. et al. The role of molecular tumor boards in neuro-oncology: a nationwide survey. BMC Cancer 24, 108 (2024).
pubmed: 38243190
pmcid: 10797778
doi: 10.1186/s12885-024-11858-x
Rahman, R. et al. Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using bayesian adaptive randomization. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 41, 5524–5535 (2023).
doi: 10.1200/JCO.23.00493
Wick, W. et al. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncol. 21, 95–105 (2019).
pubmed: 30277538
doi: 10.1093/neuonc/noy161
Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271–282 (2020).
pubmed: 31838007
doi: 10.1016/S1470-2045(19)30691-6
Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381, 626–636 (2019).
pubmed: 31166680
doi: 10.1056/NEJMoa1904059
Rodon, J. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751–758 (2019).
pubmed: 31011205
pmcid: 6599610
doi: 10.1038/s41591-019-0424-4
Hoefflin, R. et al. Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis. Cancers 13, 1151 (2021).
pubmed: 33800365
pmcid: 7962829
doi: 10.3390/cancers13051151
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
pubmed: 24695404
pmcid: 4103590
doi: 10.1093/bioinformatics/btu170
McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199
pmcid: 2928508
doi: 10.1101/gr.107524.110
Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
pubmed: 22300766
pmcid: 3290792
doi: 10.1101/gr.129684.111
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
pubmed: 21478889
pmcid: 3083463
doi: 10.1038/ng.806
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinforma. 43, 11.10.1–11.10.33 (2013).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
pubmed: 32461654
pmcid: 7334197
doi: 10.1038/s41586-020-2308-7
Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862–D868 (2016).
pubmed: 26582918
doi: 10.1093/nar/gkv1222
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
pubmed: 29165669
doi: 10.1093/nar/gkx1153
Li, Q. & Wang, K. InterVar: clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. Am. J. Hum. Genet. 100, 267–280 (2017).
pubmed: 28132688
pmcid: 5294755
doi: 10.1016/j.ajhg.2017.01.004
Chang, M. T. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Cancer Discov. 8, 174–183 (2018).
pubmed: 29247016
doi: 10.1158/2159-8290.CD-17-0321
Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155–163 (2016).
pubmed: 26619011
doi: 10.1038/nbt.3391
Liu, X., Li, C., Mou, C., Dong, Y. & Tu, Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 12, 103 (2020).
pubmed: 33261662
pmcid: 7709417
doi: 10.1186/s13073-020-00803-9
Uhrig, S. et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 31, 448–460 (2021).
pubmed: 33441414
pmcid: 7919457
doi: 10.1101/gr.257246.119
Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
pubmed: 15461798
pmcid: 545600
doi: 10.1186/gb-2004-5-10-r80
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747–1756 (2018).
pubmed: 30341162
pmcid: 6211645
doi: 10.1101/gr.239244.118
Metzger, P. et al. MIRACUM-Pipe: an adaptable pipeline for next-generation sequencing analysis, reporting, and visualization for clinical decision making. Cancers 15, 3456 (2023).
pubmed: 37444566
pmcid: 10340358
doi: 10.3390/cancers15133456
Unberath, P. et al. Searching of clinical trials made easier in cBioPortal using patients’ genetic and clinical profiles. Appl. Clin. Inform. 13, 363–369 (2022).
pubmed: 35354211
pmcid: 8967483
doi: 10.1055/s-0042-1743560
Buechner, P. et al. Requirements analysis and specification for a molecular tumor board platform based on cBioPortal. Diagnostics 10, 93 (2020).
pubmed: 32050609
pmcid: 7167859
doi: 10.3390/diagnostics10020093
Ratliff, M. et al. Patient-derived tumor organoids for guidance of personalized drug therapies in recurrent glioblastoma. Int. J. Mol. Sci. 23, 6572 (2022).
pubmed: 35743016
pmcid: 9223608
doi: 10.3390/ijms23126572
Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018).
pubmed: 29539639
pmcid: 6093218
doi: 10.1038/nature26000
Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 28, 1963–1972 (2010).
doi: 10.1200/JCO.2009.26.3541
van den Bent, M. J. et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 12, 583–593 (2011).
pubmed: 21474379
doi: 10.1016/S1470-2045(11)70057-2